Fucoidan as an anti-inflammatory and immunomodulatory agent in humans: a systematic review of clinical evidence and translational potential
- 2 November 2026
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 17 (21) , 9389-9400
Abstract
Fucoidan, a sulphated polysaccharide from brown seaweeds, has proposed anti-inflammatory and immunomodulatory properties. Clinical evidence suggests potential benefits, but remains limited, heterogeneous and inconsistent.Keywords
Funding Information
- University of Melbourne
This publication has 34 references indexed in Scilit:
- Fucoidan: A promising natural therapeutic agent for protecting human kidney healthFood Hydrocolloids for Health, 2026
- Computational insights into fucoidan–receptor binding: Implications for fucoidan-based targeted drug deliveryDrug Discovery Today, 2025
- Comparative study on the extraction methods, characterization, and bioactivity of crude fucoidan, a polysaccharide derived from Sargassum ilicifoliumBiochemical Engineering Journal, 2024
- Pharmacokinetics of fucoidan and low molecular weight fucoidan from Saccharina japonica after oral administration to miceJournal of Oceanology and Limnology, 2023
- A state-of-the-art review on fucoidan as an antiviral agent to combat viral infectionsCarbohydrate Polymers, 2022
- A review about brown algal cell walls and fucose-containing sulfated polysaccharides: Cell wall context, biomedical properties and key research challengesCarbohydrate Polymers, 2017
- Sulfated glycans in inflammationEuropean Journal of Medicinal Chemistry, 2015
- General Characteristics of Algae2015
- Algal fucoidan: structural and size-dependent bioactivities and their perspectivesApplied Microbiology and Biotechnology, 2011
- Affinity of low molecular weight fucoidan for P-selectin triggers its binding to activated human plateletsBiochimica et Biophysica Acta (BBA) - General Subjects, 2009